CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
加速 CAR-T/NK 治疗可及性——AlloCAR 与快速生产平台是否为改善多发性骨髓瘤可及性的前路？
英文原题：Accelerating accessibility of CAR-T/NK therapies - Are AlloCARs and rapid manufacturing platforms the road ahead in improving access in multiple myeloma?
查看英文原题
Accelerating accessibility of CAR-T/NK therapies - Are AlloCARs and rapid manufacturing platforms the road ahead in improving access in multiple myeloma?
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CAR-T 疗法的出现为复发/难治性多发性骨髓瘤带来了高效治疗的新纪元，但自体产品生产周期长以及单采和/或制造失败仍严重限制患者可及性。目前仍处于研究阶段的异体过继性细胞治疗产品（CAR-T、CAR-NK）属于“现成型”产品，有望缓解供应和制造瓶颈。可将过继性细胞治疗产品开发时间缩短数周的新型快速制造平台正在临床试验中接受评估，也可能有助于弥合供需缺口。本综述全面概述了正在开发的异体过继性细胞疗法和快速制造平台。
展开英文摘要原文
While the advent of CAR-T therapies has heralded a new era of efficacious therapies in relapsed/refractory Multiple Myeloma, access continues to be a major limiting factor due to prolonged manufacturing times of autologous products and apheresis and/or manufacturing failures. Allogeneic adoptive cellular therapy products (CAR-T, CAR-NK), currently investigational, are "off-the-shelf" products that may address availability and manufacturing bottlenecks.
Novel rapid manufacturing platforms that decrease adoptive cell therapy product development time by weeks are currently being tested in clinical trials and may additionally help bridge the demand-supply chasm. This review provides a comprehensive overview of allogeneic adoptive cellular therapies and rapid manufacturing platforms in development.
论文信息
- 作者
- Rajeeve S、Hoskote A、Mailankody S
- 单位
- Myeloma & Cell Therapy Services, Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address: rajeeves@mskcc.org.United States
- 文献类型
- 综述
- 期刊
- Seminars in hematology2024 Oct
- 原文标识
- PubMed 39370354 · DOI 10.1053/j.seminhematol.2024.09.001